Domvanalimab & Zimberelimab: Gastric/Esophageal Cancer Trial
Promising New Drug Combination Shows Benefit in Advanced Cancers In a significant development for cancer treatment, a novel combination therapy is demonstrating encouraging results in patients battling advanced gastric, gastroesophageal junction, and esophageal cancers. The treatment regimen, featuring domvanalimab and zimberelimab alongside standard FOLFOX chemotherapy, was presented at the ESMO Congress 2025 and detailed in … Read more